The National Institute for Health and Care Excellence

New AI tools could help spot prostate cancer more accurately

Innovative AI technologies have the potential to act like a ‘second pair of eyes’, helping radiologists review prostate MRI scans.
National Institute for Health and Care Excellence

News, blogs and podcasts

Around 1,000 people with HER2-low advanced breast cancer can now be offered Enhertu after NICE recommended it for routine NHS use. People with obsessive-compulsive disorder (OCD) and body dysmorphic ...
National Institute for Health and Care Excellence

Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism

This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots, including deep vein thrombosis and pulmonary embolism) in people aged 16 and over in hospital. It ...
National Institute for Health and Care Excellence

Prostate cancer

All NICE products on prostate cancer. Includes any guidance, advice and quality standards.
National Institute for Health and Care Excellence

Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer (terminated evaluation)

NICE is unable to make a recommendation on lurbinectedin (Zepzelca) with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer in adults. This is because the company ...
National Institute for Health and Care Excellence

Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults

This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z‑drugs and antidepressants in primary and secondary care. It does not ...
National Institute for Health and Care Excellence

Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
National Institute for Health and Care Excellence

Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours

There is a simple discount patient access scheme for anhydrous sodium thiosulfate. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can ...
National Institute for Health and Care Excellence

Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education

This guideline covers support for disabled children and young people with severe complex needs, from birth to 25 years. It aims to encourage education, health and social care services to work together ...
National Institute for Health and Care Excellence

Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over

Evidence-based recommendations on dabrafenib (Finlee) with trametinib (Spexotras) for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over. There are simple ...
National Institute for Health and Care Excellence

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) ovarian, fallopian tube or peritoneal cancer after response to first-line ...
National Institute for Health and Care Excellence

BMI: preventing ill health and premature death in black, Asian and other minority ethnic groups

This guidance has been updated and replaced by obesity: identification, assessment and management ...